2024-05-24 14:48:52 ET
Summary
- The stock of Cytokinetics, Incorporated plunged 17% in trading on Thursday, largely as the result of a somewhat botched capital raise announcement.
- The capital raise took a near-term buyout off the table in the short term and left many shareholders feeling more than disheartened.
- However, the company's primary drug candidate is likely to be approved in 2025 and has blockbuster potential.
- With the capital raise, the company has funding in place to support commercialization and the initial rollout of this asset.
- An updated analysis around Cytokinetics follows in the paragraphs below after yesterday's pullback in the shares.
Today, we are circling back to Cytokinetics, Incorporated ( CYTK ) after our recent article on this biotech name early in April. The stock dropped just over 17% in trading on Thursday after the company announced a major capital raise . We take a look at the details of that funding effort and update our analysis around the company's current prospects in the paragraphs below....
Read the full article on Seeking Alpha
For further details see:
Cytokinetics Decides To Go It Alone